Imbruvica Európai Unió - szlovák - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Brukinsa Európai Unió - szlovák - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastické činidlá - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Levact 2,5 mg/ml Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

levact 2,5 mg/ml

pharmaand gmbh, rakúsko - bendamustín - 44 - cytostatica

Bendamustine Kabi 2,5 mg/ml Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bendamustine kabi 2,5 mg/ml

fresenius kabi s.r.o., Česká republika - bendamustín - 44 - cytostatica

Bendamustine Glenmark 2,5 mg/ml Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bendamustine glenmark 2,5 mg/ml

glenmark pharmaceuticals s.r.o., Česká republika - bendamustín - 44 - cytostatica

Bendamustine Pharmagen 2,5 mg/ml Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bendamustine pharmagen 2,5 mg/ml

pharmagen cz s.r.o., Česká republika - bendamustín - 44 - cytostatica

Ledufan 2,5 mg/ml Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ledufan 2,5 mg/ml

egis pharmaceuticals plc, maďarsko - bendamustín - 44 - cytostatica

Bendamustine Mylan 2,5 mg/ml Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bendamustine mylan 2,5 mg/ml

mylan s.a.s., francúzsko - bendamustín - 44 - cytostatica

Bendamustine Accord 2,5 mg/ml prášok na infúzny koncentrát Szlovákia - szlovák - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bendamustine accord 2,5 mg/ml prášok na infúzny koncentrát

accord healthcare polska sp. z o.o., poľsko - bendamustín - 44 - cytostatica

Polivy Európai Unió - szlovák - EMA (European Medicines Agency)

polivy

roche registration gmbh - polatuzumab vedotin - lymfóm b-buniek - antineoplastické činidlá - polivy v kombinácii s bendamustine a rituximab je indikovaný na liečbu dospelých pacientov s relapsed/žiaruvzdorné plošných veľké b-buniek lymfóm (dlbcl), ktorí nie sú kandidátmi na hematopoetickú transplantácii kmeňových buniek. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).